204 related articles for article (PubMed ID: 22516257)
1. Targeting nonclassical oncogenes for therapy in T-ALL.
Subramaniam PS; Whye DW; Efimenko E; Chen J; Tosello V; De Keersmaecker K; Kashishian A; Thompson MA; Castillo M; Cordon-Cardo C; Davé UP; Ferrando A; Lannutti BJ; Diacovo TG
Cancer Cell; 2012 Apr; 21(4):459-72. PubMed ID: 22516257
[TBL] [Abstract][Full Text] [Related]
2. PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.
Efimenko E; Davé UP; Lebedeva IV; Shen Y; Sanchez-Quintero MJ; Diolaiti D; Kung A; Lannutti BJ; Chen J; Realubit R; Niatsetskaya Z; Ten V; Karan C; Chen X; Califano A; Diacovo TG
Mol Cancer Ther; 2017 Oct; 16(10):2069-2082. PubMed ID: 28716817
[TBL] [Abstract][Full Text] [Related]
3. Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Lim EL; Cugliandolo FM; Rosner DR; Gyori D; Roychoudhuri R; Okkenhaug K
JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875319
[TBL] [Abstract][Full Text] [Related]
4. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
Burger JA; Okkenhaug K
Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
[TBL] [Abstract][Full Text] [Related]
5. PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors.
Lonetti A; Cappellini A; Spartà AM; Chiarini F; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; McCubrey JA; Martelli AM
Oncotarget; 2015 Apr; 6(12):10399-414. PubMed ID: 25871383
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.
Ali AY; Wu X; Eissa N; Hou S; Ghia JE; Murooka TT; Banerji V; Johnston JB; Lin F; Gibson SB; Marshall AJ
Leukemia; 2018 Sep; 32(9):1958-1969. PubMed ID: 29479062
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies.
Kim YS; Cheon MG; Boggu PR; Koh SY; Park GM; Kim G; Park SH; Park SL; Lee CW; Kim JW; Jung YH
Bioorg Med Chem; 2021 Sep; 45():116312. PubMed ID: 34332211
[TBL] [Abstract][Full Text] [Related]
9. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
[TBL] [Abstract][Full Text] [Related]
10. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
11. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
[TBL] [Abstract][Full Text] [Related]
12. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
13. Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.
Martinez NG; Thieker DF; Carey LM; Rasquinha JA; Kistler SK; Kuhlman BA; Campbell SL
J Mol Biol; 2021 Apr; 433(8):166838. PubMed ID: 33539876
[TBL] [Abstract][Full Text] [Related]
14. Miltefosine suppression of Pten null T-ALL leukemia via β-catenin degradation through inhibition of pT308-Akt and TGFβ1/Smad3.
Zhang Y; Lee S; Xu W
Biochem Biophys Res Commun; 2020 Apr; 524(4):1018-1024. PubMed ID: 32063363
[TBL] [Abstract][Full Text] [Related]
15. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
[TBL] [Abstract][Full Text] [Related]
16. Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus.
Ferguson MS; Chard Dunmall LS; Gangeswaran R; Marelli G; Tysome JR; Burns E; Whitehead MA; Aksoy E; Alusi G; Hiley C; Ahmed J; Vanhaesebroeck B; Lemoine NR; Wang Y
Mol Ther; 2020 May; 28(5):1263-1275. PubMed ID: 32145202
[TBL] [Abstract][Full Text] [Related]
17. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
18. PI3Kδ inhibition hits a sensitive spot in B cell malignancies.
Vanhaesebroeck B; Khwaja A
Cancer Cell; 2014 Mar; 25(3):269-71. PubMed ID: 24651009
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and bioactivity evaluation of a series of quinazolinone derivatives as potent PI3Kγ antagonist.
Liang Y; Zheng Y; Yang J; Ke J; Cheng K
Bioorg Med Chem; 2023 Apr; 84():117261. PubMed ID: 37011446
[TBL] [Abstract][Full Text] [Related]
20. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.
Xin M; Duan W; Feng Y; Hei YY; Zhang H; Shen Y; Zhao HY; Mao S; Zhang SQ
Bioorg Med Chem; 2018 May; 26(8):2028-2040. PubMed ID: 29534936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
